For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for TransMedics Group Inc. (TMDX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -24 (−100…+100 Quality+Value blend) · Quality 29 · Value -68 · Sentiment -59 (timing only, not weighted) · Composite fair value $21.81 vs $76.51 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
TransMedics Group Inc.
TMDX NASDAQTransMedics Group Inc. is a commercial-stage medical technology company specializing in advanced systems and services for solid organ transplantation. Headquartered in Andover, Massachusetts, it focuses on improving the preservation, assessment, and transport of donor hearts, lungs, and livers for patients with end-stage organ failure. The company’s core platform, the Organ Care System, is a portable normothermic perfusion technology that keeps donor organs functioning in a near-physiologic state outside the body, enabling clinicians to evaluate and optimize organ quality prior to transplant. TransMedics combines this device platform with a service-led model that includes its National OCS Program, offering end-to-end organ retrieval, clinical management, logistics coordination, and dedicated transportation for transplant centers across the United States. Operating in the high-acuity transplant ecosystem, TransMedics plays a critical role in organ transplant workflows by helping transplant programs increase organ utilization and support complex heart, lung, and liver procedures through integrated technology and clinical services.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.87
Total Equity: $473.10M
Shares: 40,540,694
Total Debt: $10.00M
Cash: $488.87M
EBITDA: $135.77M
Total Debt: $10.00M
Cash: $488.87M
Revenue: $605.49M
Revenue: $605.49M
Revenue: $605.49M
Total Equity: $473.10M
Tax Rate: -77.0%
Equity: $473.10M
Total Debt: $10.00M
Cash: $488.87M
Current Liabilities: $89.31M
Long-Term Debt: $0.00
Total Debt: $10.00M
Total Equity: $473.10M
Shares: 40,540,694
Shares: 40,540,694
CapEx: -$59.25M
Shares: 40,540,694
Stock Price: $76.51
Net Income: $190.29M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 2, 2026 2:47pm (21d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $93.5M | $241.6M | $441.5M | $605.5M |
| Cost of Revenue | $9.1M | $28.2M | $87.5M | $179.5M | $242.7M |
| Gross Profit | $21.2M | $65.3M | $154.1M | $262.1M | $362.8M |
| Operating Expenses | $60.6M | $96.7M | $182.8M | $224.6M | $254.2M |
| Operating Income | -$39.4M | -$31.4M | -$28.7M | $37.5M | $108.6M |
| Net Income | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190.3M |
| EBITDA | -$37.6M | -$28.0M | -$20.6M | $57.3M | $135.8M |
| EPS | $-1.60 | $-1.23 | $-0.77 | $1.07 | $5.60 |
| EPS (Diluted) | $-1.60 | $-1.23 | $-0.77 | $1.01 | $4.87 |
Balance Sheet (Annual)
Last updated: Aug 2, 2026 2:20pm (21d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $26.1M | $201.7M | $395.3M | $337.2M | $488.9M |
| Total Current Assets | $118.7M | $252.3M | $510.7M | $497.2M | $637.8M |
| Total Assets | $134.9M | $277.1M | $706.0M | $804.1M | $1.1B |
| Current Liabilities | $23.2M | $23.7M | $54.9M | $59.9M | $89.3M |
| Long-Term Debt | $35.2M | $58.7M | — | — | — |
| Total Liabilities | $67.0M | $89.8M | $568.8M | $575.5M | $595.3M |
| Total Equity | $67.9M | $187.4M | $137.2M | $228.6M | $473.1M |
| Retained Earnings | -$442.4M | -$478.7M | -$503.7M | -$468.2M | -$278.0M |
Cash Flow (Annual)
Last updated: Aug 2, 2026 2:47pm (21d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$28.9M | -$45.8M | -$13.0M | $48.8M | $192.8M |
| Capital Expenditure | -$3.5M | -$11.9M | -$151.8M | -$129.7M | -$59.3M |
| Free Cash Flow | -$32.4M | -$57.7M | -$164.9M | -$80.9M | $133.6M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | $22.5M | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $999,000 | $175.6M | $193.6M | -$58.2M | $151.7M |
Growth Trends (YoY %)
Last updated: Aug 2, 2026 2:47pm (21d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +208.8% | +158.5% | +82.7% | +37.1% |
| Gross Profit Growth | +208.5% | +136.1% | +70.1% | +38.4% |
| Operating Income Growth | +20.3% | +8.6% | +230.5% | +189.6% |
| Net Income Growth | +18.1% | +30.9% | +241.7% | +436.6% |
| EBITDA Growth | +25.7% | +26.5% | +378.6% | +137.1% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 11:09Recovery pays +52%; another quarter like the worst recent one costs 67%. Ratio 0.8:1.
| Case | Growth | Margin | Fair value | vs price ($76.51) |
|---|---|---|---|---|
| Bull — recovery | +54% | 26.1% | $116.43 | +52% |
| Base — stabilizes | +36% | 22.7% | $65.86 | -14% |
| Bear — keeps slipping | +18% | 19.3% | $35.53 | -54% |
| Stress — last quarter repeats | +21% | 11.4% | $25.45 | -67% |
Narrative Economics
market-narrative step).
Claude Reading
The raw trajectory here is genuinely impressive but the deceleration story is real and being underweighted by the bulls. Revenue went from $30M (2021) to $605M (2025) — a 20x in four years — but the quarter-over-quarter cadence tells a different story: Q1'25 $143.5M → Q2 $157.4M → Q3 $143.8M (sequential decline) → Q4 $160.8M → Q1'26 $173.9M. That's roughly 21% annualized sequential growth off the recent base, not 58%. YoY of 37% for the latest quarter (Q1'26 vs Q1'25 $173.9M vs $143.5M) is fine but decelerating hard from the 60%+ prints of 2024. The Q4'25 net income of $105M on $161M revenue (65.6% margin) is a massive tax/one-time benefit distortion — normalized margins are running 15-20%, not 31%. The synthesis leaning on "31% net margins" as structural is misleading; strip the Q4 anomaly and full-year NI is closer to $85M, or ~14% net margin. That materially changes the P/E from 15.7x to ~31x on normalized earnings.
I mostly agree with the synthesis verdict of overvalued but I think the $26 fair value is too punitive and the $76 price isn't as insane as the DCF suggests. The bear DCF appears to assume rapid mean-reversion of growth, which contradicts the sector-leader positioning in a genuinely underpenetrated market (OCS is the only FDA-approved platform of its kind for heart, lung, liver). At 4.4x sales with 60% gross margins, ~$130M FCF and $479M net cash, this is not a bubble — it's a growth stock being asked to prove the next leg. My rough fair value: on $700M 2026 revenue at 5-6x sales for a decelerating-but-dominant medtech with expanding margins, you get $50-60. So the composite $26 looks like a DCF using a punishing terminal multiple; the market's $76 assumes reacceleration. Truth is probably in the $50s.
The contrarian bull case that the models underweight: TMDX owns the aircraft and logistics network (National Aviation Program) — this is not a pure device company, it's vertical integration in organ transport, which creates a real moat and explains why gross margins compressed but revenue scaled. If OCS moves toward standard-of-care for extended-criteria donors (which is where the clinical evidence is pointing), the TAM math changes materially. The insider activity is neutral-to-slightly-positive: mostly awards, one small S-Sale of 9,624 shares against a 19,285 option exercise — that's routine tax-cover, not conviction-signaling exit. The narrative layer flagging "cult coefficient medium" is right — this isn't a retail meme, it's institutional impact capital, which is stickier than the DCF-only view assumes. The contrarian bear case that also gets underweighted: Q3'25's sequential decline to $143.8M was a warning shot the market largely ignored, and if reimbursement scrutiny hits (CMS has been reviewing organ procurement economics), the whole revenue model gets repriced.
Committing: I partially dissent from the synthesis. Overvalued directionally — yes — but $26 fair value is a low-conviction number that overweights DCF sensitivity to terminal growth. My read is fair value $50-60, current $76 embeds 25-50% of premium for continued adoption inflection that has not been proven in the last three quarters of sequential data. The Q1'26 acceleration to $173.9M is encouraging but one print doesn't reverse the deceleration trend. I'd want to see two consecutive quarters of >10% sequential growth and clarity on the Q4'25 tax benefit before adding. The thesis evaluation score of -5 (essentially balanced) is closer to my read than the synthesis' emphatic overvalued call. This is a hold-if-you-own-it, wait-for-$55-to-buy, don't-short situation — the balance sheet ($489M cash, $10M debt, current ratio 7.1) makes shorting expensive and the clinical narrative can reassert on any single positive reimbursement or adoption datapoint. Regime caveat: the "2026-03-31" and "2026-07-10" dates suggest this data is forward-dated or the file has date errors — that's a real anomaly worth flagging before sizing any position.
GPT Reading
What stands out is that the stock is being discussed like a fragile concept story when the numbers now look like a scaled, cash-generating medtech platform. Revenue went from $241.6M in 2023 to $441.5M in 2024 and $605.5M in 2025, a 151% two-year increase, while operating income swung from -$28.7M to +$37.5M to +$108.6M. Even stripping out the obviously non-recurring distortion in 4Q25 net income of $105.4M on $160.8M of sales, the business is profitable on a run-rate basis: the last five “normal” quarters before 1Q26 averaged roughly 14%-22% net margins, and 1Q26 still produced $7.3M of net income despite a margin drop to 4.2%. On valuation, the raw multiples are not demanding for a company that is still growing this fast: 5.1x sales, 15.7x earnings, and about 16x EV/EBITDA, backed by $488.9M of cash against just $10.0M of debt. Enterprise value is only modestly above 3.5x trailing revenue for a business that just grew annual sales 37% and generated $133.6M of free cash flow.
The key issue is not whether TransMedics is “real” — it clearly is — but whether the recent slowdown means the hypergrowth phase is ending. 1Q26 revenue of $173.9M was up 21.2% year over year from $143.5M, which is still strong but meaningfully below the 37% recent growth marker and below the 2024-to-2025 annual growth rate of 37.1%. Quarterly sequencing also matters: revenue rose from $143.5M in 1Q25 to $157.4M in 2Q25, then slipped to $143.8M in 3Q25 before recovering to $160.8M in 4Q25 and $173.9M in 1Q26. That is growth, but not the smooth compounding line bulls prefer. More importantly, margins look volatile enough to warn against annualizing the 2025 headline earnings figure. Full-year 2025 net margin was 31.4%, but that was inflated by the 65.6% margin in 4Q25; by contrast, 1Q26 reverted hard to 4.2%. So I do not buy the idea that this deserves a premium because 30%-plus net margins are “proven.” What is proven is strong gross margin near 60% and emerging operating leverage, not a stable earnings power anywhere close to $190M net income.
That said, the market appears to have overreacted in the opposite direction. If I haircut earnings materially and think in EV/revenue and normalized free cash flow rather than the distorted 2025 net income, the current price still looks closer to attractive than dangerous. A company with $605.5M of trailing revenue, positive operating income over $100M, FCF of $133.6M, and a fortress balance sheet is not obviously overvalued at a $2.64B market cap unless one assumes a sharp growth air pocket or structural margin collapse. The most bearish framework in the briefing leans heavily on a DCF fair value around $26, but that seems anchored to conservative current-period cash flows while underweighting the fact that this company has already crossed from commercialization burn to self-funded scale. For a category leader in a clinically differentiated niche, 3.6x EV/revenue is not a heroic multiple. My read is that the stock is being valued as if 2025 was a one-off peak, whereas the underlying data still support a business that can grow into a meaningfully higher value even with margin normalization.
The strongest argument against this view is that 1Q26 may be the first clean evidence that the model is less scalable than the trailing numbers suggest. Revenue growth slowed to 21%, net margin nearly disappeared, and the quarterly cadence has been choppy for a company whose bull case depends on standard-of-care adoption. A smart bear would also point out that healthcare logistics-heavy models can look fantastic until utilization, reimbursement, or operating complexity bites, and the strange combination of very high ROE at 40.2% with deeply negative reported ROIC suggests the canonical metrics are not giving a clean picture of capital efficiency. If normalized earnings are closer to, say, a low-double-digit net margin on $650M-$700M of revenue rather than the 31% trailing margin, then today’s P/E is flattering and the stock is more like a mid-20s to 30x true earnings story. Add in some insider selling, however modest relative to awards and exercises, and it is easy to argue that this is not cheap enough for an execution-sensitive medtech name after all.
What would change my mind is straightforward. If the next two quarters show revenue stalling in the $170M range or dropping below 20% year-over-year growth while net margin stays in the low single digits, I would conclude 2025 was peak economics and that the stock deserves a much lower multiple, likely under $60. Conversely, if revenue re-accelerates back toward 25%-30% growth with operating margin holding in the mid-teens and free cash flow conversion remaining strong, then the current multiple is too low and the shares should trade comfortably above $90. Right now the evidence says this is no longer a speculative transplant narrative but a real business with one ugly margin print; I am inclined to fade the extreme skepticism, not join it.
Grok Reading
The raw numbers show a company that has genuinely crossed into scaled profitability, not a story stock still burning cash. Revenue compounded from $30.3M in 2021 to $605.5M in 2025, with 2025 delivering $108.6M of operating income, $190.3M of net income, and $133.6M of free cash flow against only $59.3M of capex. The balance sheet is pristine: $488.9M cash, $10M debt, current ratio above 7, and debt-to-equity of 0.02. Gross margin holds near 60 percent and the trailing net margin prints at 31 percent. Those are real industrial metrics, not vapor. Yet the growth trajectory is unambiguously decelerating—208 percent, then 158 percent, 83 percent, 37 percent year-over-year, and the latest quarter (Q1 2026 revenue of $173.9M) is only up roughly 21 percent from the year-ago $143.5M. Sequential volatility is also visible: Q3 2025 revenue slipped to $143.8M before rebounding. More concerning is the earnings quality signal in the most recent print—net income collapsed to $7.3M (4.2 percent margin) after a $105.4M outlier quarter that almost certainly contained non-recurring tax or other items. Strip that noise and run-rate profitability looks closer to the $25–35M quarterly band seen earlier in 2025, implying a more modest earnings base than the headline 15.7× P/E suggests.
At $76.51 and a $2.64B market cap the stock trades at 5.1× sales, 3.6× EV/revenue and roughly 20× EV/operating income. For a med-device platform still growing above 20 percent with fortress liquidity those multiples are not grotesque, but they leave little room for further deceleration. The rule-based and narrative layers correctly flag that a large fraction of the prior premium was belief in OCS becoming standard-of-care logistics; the fundamentals have now partially validated that belief, which is why a $26 DCF fair-value output looks broken on its face—it would imply sub-1.5× sales for a company printing nine-figure FCF. Still, the market is no longer pricing hyper-growth; it is pricing mid-20s growth that the recent quarterly run-rate is already undershooting. ROIC flashing negative 33 percent while ROE sits at 40 percent is almost certainly a data artifact, but it underscores that invested-capital returns need cleaner scrutiny before one can call the model fully proven at scale.
The strongest case against this caution is straightforward: TransMedics already converted a mission narrative into $600M of revenue and $134M of FCF inside four years, maintains 60 percent gross margins, and sits on half a billion dollars of cash with negligible leverage. If OCS adoption continues to expand the usable-organ pool and the service-attach rate rises, operating leverage could push margins back toward the mid-20s and re-accelerate growth into the 30 percent range—making 5× sales look cheap and the current 15–20× earnings multiple a bargain. Clinical stickiness and the absence of a true peer competitor give the bull case a real fundamental anchor that pure-story biotech never possessed. I weigh this less heavily right now because the observed deceleration is already multi-year and the Q1 2026 margin reset shows that profitability is still lumpy; until growth stabilizes above 25 percent or margins demonstrate durability outside one-time quarters, the multiple has limited upside support.
What would flip the view is two consecutive quarters of revenue growth re-accelerating above 30 percent year-over-year together with operating margins holding above 18 percent, or clear reimbursement expansion that visibly lifts the service-revenue mix. Conversely, another quarter of sub-15 percent growth or sub-10 percent net margins would confirm the slowdown thesis and push fair value materially lower.
Big-3 Panel — where each AI stands
Claude — Second Response · overvalued revised
VERDICT: Modestly overvalued at $76; fair value $55-68 — widened upward from $50-60 acknowledging FCF/balance-sheet floor, but Q1'26 margin reset prevents the $90+ bull case until two clean quarters land
My colleagues moved me slightly toward the middle of my own range, not off it. GPT's strongest point is the one I should own more directly: at 3.6x EV/revenue, $133.6M FCF, and $479M net cash, calling this "overvalued" requires believing the growth air pocket is structural, not lumpy — and the four-year record (208% → 158% → 83% → 37%) plus the Q1'26 reacceleration to 21% YoY off a base that included a Q3'25 sequential dip is not yet that evidence. GPT is right that I was implicitly annualizing the Q1'26 4.2% net margin fear while simultaneously discounting the 60% gross margin structural story. Those don't both get to be true. Fair.
But GPT's $90-100 requires margins normalizing above 10% AND growth staying above 20% — and the Q1'26 print delivered exactly one of those two, with the margin miss being the more alarming variable because it's what the bull multiple rests on. Grok's framing is closest to mine and actually tightens it: $55-65 with the same deceleration-plus-margin-reset logic, and Grok explicitly called the $26 DCF "broken on its face" for a company printing nine-figure FCF, which is the point I was making less crisply. Where I'll revise: my $50-60 range was probably 5-10% too low given the balance sheet optionality and the fact that shorting into $479M net cash and a genuine clinical moat is a bad trade. I'll widen to $55-68 and acknowledge the asymmetry isn't as clean as I framed it.
What did NOT move me: GPT's implicit assumption that 2025 operating income of $108.6M is a reasonable run-rate anchor. Q4'25 carried the year, and Q1'26 operating leverage collapsed. Until we see two quarters of mid-teens operating margin on >$170M revenue, paying 5x sales for a decelerating print is asking the multiple to do work the fundamentals haven't yet done. Hold-if-owned, buy in high-$50s, still no chase at $76.
GPT — Second Response · overvalued changed direction
VERDICT: Fairly to modestly overvalued at $76.51; I’d anchor fair value around $55-$65 today, with >$85 requiring renewed 25-30% growth and mid-teens-plus margins.
Claude’s point that most moved me is not the broad “deceleration” claim—I already had that—but the normalization math: if you back out the obviously anomalous 4Q25 tax/one-time benefit, 2025 earnings power is closer to ~$85M, not $190M. That effectively doubles the “real” P/E from the optically cheap mid-teens to roughly 30x, which is a meaningful hit to my original undervaluation case because I leaned more heavily on EV/revenue and FCF than on how flattering reported earnings were. Grok reinforces the same issue from another angle: the latest quarter did not merely slow; it reset net margin to 4.2%, showing that the model’s earnings power is still much less settled than trailing annual numbers imply. I also think Claude’s framing of the current setup as “not a bubble, but being asked to prove the next leg” is more faithful to the data than my earlier “fade the skepticism” stance.
What did not move me is the most bearish valuation logic. Both colleagues rightly reject the $26 DCF outcome, and I do too; sub-1.5x sales for a clinically differentiated, cash-rich category leader with ~$600M revenue and $133.6M FCF is too punitive absent a genuine structural break. The balance sheet, gross margins near 60%, and unique logistics/device integration still argue against an outright bearish posture. But I am revising because the stock no longer looks clearly cheap on normalized economics. At ~$76, investors are paying for a reacceleration that the recent quarterly cadence has not yet earned. Fair value in the mid-$50s to mid-$60s now seems more defensible than my prior $90-$100 range unless the next two quarters show both better growth and restored operating leverage.
Grok — Second Response · overvalued held
VERDICT: Modestly overvalued at $76; fair value $55-65 until growth re-accelerates and margins stabilize
Claude’s normalization of 2025 earnings lands hardest and keeps me from drifting. Stripping the $105 M Q4 tax distortion leaves roughly $85 M of true net income (~14 % margin), turning the headline 15.7× P/E into something closer to 31× on a $2.64 B market cap. That single adjustment, which GPT under-weights when he still cites the raw trailing multiple, confirms that current pricing already embeds optimistic durability. GPT’s claim that 3.6× EV/revenue is “not heroic” for a still-growing platform is directionally fair, yet it collides with the multi-year deceleration already visible: 208 % → 158 % → 83 % → 37 % → 21 % YoY, plus the Q3 sequential drop that both colleagues note. A 20 %-growth med-tech with lumpy mid-teens margins does not automatically clear 5× sales; the burden of proof now sits on re-acceleration, not on the market’s willingness to pay up for past compounding.
Claude’s $50-60 fair-value band and emphasis on vertical logistics moat are useful but do not change the arithmetic. The aircraft network and OCS clinical stickiness are real differentiators, yet they have not prevented sequential choppiness or the Q1 margin collapse to 4.2 %. Until two clean quarters show >25 % growth and operating margins holding above 15 %, the $76 price still capitalizes an adoption inflection that the last four prints have failed to deliver. GPT’s $90-100 upside case therefore requires assumptions the recent data contradict; I leave it on the table only as a contingent bull scenario, not base case.
I hold the original caution. Fair value remains $55-65; the stock is modestly overvalued until the growth and margin trajectory re-proves itself.
Advanced Analysis Forensic deep-dive · separate lenses
The business transformation is genuine: revenue scaled from $30M in 2021 to $605M in 2025 (roughly 110% CAGR), operating margin flipped from -130% to +17.9%, and FCF swung from -$165M in 2023 to +$134M in 2025. Net income of $190M in 2025 is largely cash-backed (OCF/NI 0.97x, accruals -2.3% of assets), and the balance sheet is a fortress with $489M liquid cash, $479M net cash, and Altman Z of 3.82. Classification as high-growth-profitable is warranted by the data.
Verify before trusting this (5)
- Whether GM compression from 69.9% to 59.9% reflects mix (NOP heart/liver vs lung), pricing, or logistics/aviation cost absorption
- Customer/transplant-center concentration and payer reimbursement stability
- Detail behind the Beneish flag — receivables days, DSO trend, and any capitalized costs
- Whether SBC grant velocity moderates now that the company is GAAP profitable
- Sustainability of the FCF swing (working capital release vs recurring)
The e2e composite lands at $24.78 with a signal-adjusted FV of $26.29, implying roughly -66% downside from $76.51. That anchor is an EPV-floor read, so it deliberately understates a hyper-growth story - but even generously tripling it to reflect the revenue trajectory (20x in four years, margin inflection, fortress balance sheet) only gets you into the $60-75 zone, i.e. fair at best. The market cap of $2.64B on a business still scaling with thin margins requires the OCS platform to compound for many more years without reimbursement, logistics, or competitive setbacks.
Verify before trusting this (5)
- Forward revenue guidance and NOP (National OCS Program) utilization trends
- Gross margin trajectory - is the recent slide temporary or structural?
- Segment mix (heart vs lung vs liver) and reimbursement updates
- Share count guidance and SBC run-rate for per-share math
- Beneish M-score components - what is driving the flag?
TMDX is a classic narrative-priced medical device story: the OCS organ-preservation platform carries a strong mission-driven bull thesis with moderate durability and medium cult following. But the story took real damage on May 6 when a 51% EPS miss and margin compression triggered a 23% single-day sell-off, and recent momentum (37% vs 58% long-term CAGR) confirms the narrative is decelerating, not accelerating. That is the exact wrong shape for a stock priced at $76.51 vs a $26.29 DCF - almost the entire market cap is story, and the story just cracked. The macro tape is only mildly supportive (regime +22, VIX 16) and offers no real tailwind to a beta-1.88 unprofitable-story name; if the S&P wobbles further off its high, high-beta narrative healthcare gets marked down first. Rates at 4.68% and a market PE of 26.9 add background pressure on long-duration adoption stories exactly like this one. Net: the narrative is intact but bruised, analyst tone is likely still catching down to the Q1 print, and there is no sector rotation or macro impulse actively pushing this name higher. The pressure leans headwind, not catastrophic - the story has not broken, just wobbled.
Verify before trusting this (5)
- Q2 print - does revenue growth reaccelerate or does the margin compression story deepen?
- Analyst target revisions post-Q1 - are sell-side cuts done or still trickling in?
- OCS adoption datapoints from major transplant centers - any signs the surgeon-behavior bear case is playing out?
- Any move in VIX above 20 or S&P down more than 5% - would disproportionately punish this beta-1.88 name
- Reimbursement newsflow (CMS, private payors) - the single biggest narrative swing factor
This lens hasn't been run for this ticker yet.